Browse the evidence

Standardized resistance training protocols produce wide, idiosyncratic variation in clinical outcomes (glucose metabolism, strength, body composition) among adherent prediabetic adults, necessitating personalized adaptive interventions rather than one-size-fits-all approaches.

If you are doing resistance training and not seeing expected improvements in blood sugar or strength despite attending all sessions, do not assume you are failing. Your body may simply be a 'non-responder' to that specific stimulus. Consult a professional to adapt your program (e.g., change exercise type, intensity, or add dietary interventions) rather than just increasing effort.

Responsiveness to resistance training for one outcome (e.g., strength) is not necessarily associated with responsiveness for other outcomes (e.g., glucose metabolism or blood pressure), indicating outcome-specific responses.

Do not assume that getting stronger will automatically fix your blood sugar or blood pressure. If your strength improves but your metabolic markers do not, you may need to add specific interventions (like dietary changes or different exercise types) to address those specific risks.

Metabolic adaptation (reduced energy expenditure beyond that predicted by body composition changes) occurs during active weight loss but typically normalizes after body weight stabilizes, although it may persist long-term in specific contexts such as extreme caloric restriction.

When you lose weight, your body burns fewer calories, but this is largely because you weigh less and have less metabolically active tissue. While your metabolism may stay lower than it was at your starting weight for a while, it often normalizes once your weight stabilizes. Don't assume long-term failure is inevitable; focus on maintaining your new weight, as the metabolic penalty is often overstated and may resolve over time.

Low-carbohydrate diets lead to significant short-term reductions in body weight, BMI, and waist circumference in overweight/obese T2DM patients, but these advantages may attenuate over the long term (6-24 months) compared to balanced low-calorie diets.

You can expect to lose weight, BMI, and waist circumference quickly in the first few months on a low-carb diet. However, do not be discouraged if your weight loss slows down after 6 months; studies show that over the long term, your results will likely be similar to those of any balanced, calorie-controlled diet. The key is sustainability and adherence rather than expecting indefinite rapid loss.

Tirzepatide utilization has rapidly displaced other glucose- and weight-lowering medications in the US, with its uptake being steeper and more sustained than previous GLP-1 receptor agonists.

Tirzepatide is currently the fastest-growing and most prescribed glucose- and weight-lowering medication in the US, rapidly replacing older drugs like metformin and other GLP-1s. If you have T2D or obesity, this drug is becoming the standard of care, but access may be difficult due to shortages. Prioritize securing a prescription early if eligible.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, achieves up to 24.2% weight loss over 48 weeks.

Retatrutide is an investigational once-weekly injection that targets GLP-1, GIP, and glucagon receptors, achieving up to 24.2% weight loss over 48 weeks in clinical trials. It is not yet fully approved but shows promise for obesity and type 2 diabetes. Potential side effects include gastrointestinal issues and transient heart rate elevations.

Intensive lifestyle intervention in patients with Type 2 Diabetes and obesity does not significantly reduce major cardiovascular events compared to standard care, although weight loss of 10% or more is associated with a lower risk.

For Type 2 Diabetes patients, intensive lifestyle changes alone may not significantly reduce heart events compared to standard care, unless you achieve at least 10% weight loss. Focus on sustainable weight loss and combine lifestyle changes with medical therapies for best heart protection.

GLP-1 Receptor Agonists (GLP-1RAs) improve glycemic control and promote weight loss by enhancing glucose-dependent insulin secretion, inhibiting glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways.

GLP-1RAs help control blood sugar and promote weight loss by mimicking a gut hormone that tells your body to release insulin when needed, slows down digestion, and reduces appetite. They are generally safe regarding low blood sugar but can cause stomach issues initially. Consistent use and monitoring are key to managing side effects and achieving long-term health benefits.

Regular physical activity, including aerobic, resistance, balance, and dual-task training, reduces the risk of dementia and cognitive decline by enhancing neurogenesis, improving cerebral blood flow, and increasing brain-derived neurotrophic factor (BDNF).

Aim for 150-300 minutes of moderate aerobic activity (like brisk walking) or 75-150 minutes of vigorous activity per week. Add strength and balance exercises twice a week. If you prefer cultural practices like Tai Chi or yoga, these are excellent alternatives that also support cognitive health. Start with what you enjoy and gradually increase intensity.

Adherence to Mediterranean (MedDiet) or MIND diets reduces the risk of cognitive decline and dementia by lowering inflammation and oxidative stress.

Eat more vegetables, fruits, legumes, nuts, and fish. Use olive oil instead of butter. Limit red meat and processed foods. This pattern helps reduce inflammation and supports brain health.

Post-procedure dietary quality (low processed foods, high fiber/vegetables) is more critical for sustained weight loss than the specific macronutrient ratio (low-carb vs. low-fat).

Don't obsess over whether you are low-carb or low-fat. Focus on eating whole foods, vegetables, and fruits, and keeping processed foods and added sugars under 10% of your calories. This quality matters more than the specific diet label.

Higher program website engagement (meeting a login goal of ≥90 logins in 3 months) significantly decreases the odds of early dropout.

Consistently logging into your weight-loss program's website (aiming for daily logins) is one of the best ways to ensure you stay in the program. If you find yourself skipping logins, it is a warning sign that you might drop out soon.

Having one or more chronic medical conditions significantly increases the odds of early dropout from commercial weight-loss programs.

If you have chronic health conditions, be aware that you are at higher risk for dropping out of weight-loss programs. Proactively communicate with your coach and healthcare provider to manage these competing demands.

Intermittent fasting variants (ADF, TWF, TRE) produce weight and fat loss effects equivalent to daily caloric restriction (DCR) when total energy intake is matched, with no inherent metabolic advantage to fasting timing.

Use intermittent fasting if it helps you eat less, not because you think it burns fat faster. If you can maintain a caloric deficit with standard meal timing, you will lose fat at the same rate. Prioritize protein intake and resistance training to protect muscle, as fasting does not inherently spare muscle.

GLP-1 receptor agonists and SGLT2 inhibitors are effective pharmacological treatments for T2DM and obesity that target shared pathophysiological mechanisms like inflammation and insulin resistance.

If lifestyle changes are insufficient, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs help manage blood sugar and weight by targeting hormonal pathways, offering an advantage over older medications that may cause weight gain.

Current obesity treatments (behavioral, pharmacological, surgical) are effective but often result in weight regain, and their long-term success is limited by unchanged environmental factors.

Obesity treatments are effective but not permanent cures. You need to manage your weight long-term, possibly using a combination of treatments, and be prepared for potential weight regain if you stop.

GLP-1 receptor agonists (GLP-1RAs) improve hepatic steatosis, liver dysfunction enzymes, and glycemic control in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

If you have fatty liver disease (MASLD/MASH), especially with diabetes or obesity, GLP-1 medications (like Semaglutide or Liraglutide) are a proven treatment option. They not only help lower blood sugar and promote weight loss but also directly improve liver health by reducing fat and inflammation. While lifestyle changes are foundational, these medications offer a powerful tool when lifestyle changes alone are insufficient or hard to maintain long-term. Consult your doctor to see if a GLP-1 RA is appropriate for your specific liver condition.

Pioglitazone (30-45 mg) improves hepatic steatosis and inflammation in MASH patients, particularly those with type 2 diabetes, but carries risks of weight gain and bone fractures.

Pioglitazone (30-45mg) improves liver inflammation and fat in MASH, especially for diabetics. However, it causes weight gain and increases fracture risk, so it is used cautiously.

Semolina pasta has a low to medium glycemic index (33-61) due to its dense protein-starch matrix, resulting in slower digestion and lower postprandial glucose response compared to bread or potatoes.

Cook pasta al dente to maintain its low glycemic index. This slows digestion and prevents sharp blood sugar spikes, making it a suitable option for people with diabetes or those managing insulin resistance.

In normotensive postmenopausal women with high baseline fat intake, replacing total fat with increased carbohydrate and plant-based protein significantly reduces coronary heart disease risk, whereas replacing fat with carbohydrate alone does not.

If you are a normotensive woman with high baseline fat intake, simply lowering fat is not enough to maximize heart health benefits. You must actively replace the calories from fat with plant-based proteins (like beans and legumes) and fiber. Simply replacing fat with refined carbohydrates (like sugar) does not reduce coronary heart disease risk and may even negate the benefits of the low-fat diet.

The D2O stable isotopic tracer methodology allows for the assessment of muscle protein synthesis (MPS) over extended periods (days to weeks) in free-living settings, overcoming the limitations of short-term infusion methods.

Current research methods are evolving to better understand how muscle protein synthesis works over days and weeks, not just hours. This helps us see how consistent training and nutrition actually build muscle over time, rather than just looking at immediate spikes.

Dramatic weight loss triggers a disproportionate, long-lasting reduction in resting metabolic rate (metabolic adaptation) that actively counteracts weight maintenance, making long-term maintenance of extreme weight loss biologically difficult without sustained environmental support.

If you have lost a significant amount of weight, expect your metabolism to slow down more than predicted by your new size. This is biology, not failure. To maintain your weight, you must sustain the lifestyle changes (diet and activity) that got you there, rather than returning to old habits. Monitor your weight frequently and be prepared to re-engage with your healthy behaviors if you see small gains.

Higher rates of in vivo adipose triglyceride (TG) synthesis and de novo lipogenesis (DNL) are negatively correlated with body weight loss in women with obesity.

You might think that if your body is good at making new fat (de novo lipogenesis), it would be harder to lose weight. However, this study found the opposite: women who lost more weight actually had higher rates of fat synthesis and turnover in their fat tissue. This suggests that a dynamic, active fat metabolism might be helpful for weight loss, rather than a slow, stagnant one. It highlights that fat turnover is complex and not just about 'making fat'.

In older adults with overweight/obesity and type 2 diabetes, losing weight while simultaneously gaining skeletal muscle mass significantly reduces the risk of adverse cardiovascular events compared to weight gain or weight loss accompanied by muscle loss.

For older adults with excess weight and diabetes, simply losing weight on the scale is not enough to protect the heart. You must preserve or build muscle during weight loss. This likely requires resistance exercise combined with adequate protein intake, rather than dieting alone. Losing weight while losing muscle provides no cardiovascular benefit compared to gaining weight.